The Potential and Challenges of Proton FLASH in Head and Neck Cancer Reirradiation.

FLASH radiotherapy head and neck cancers proton therapy reirradiation stereotactic body radiation therapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
24 Sep 2024
Historique:
received: 11 07 2024
revised: 17 09 2024
accepted: 19 09 2024
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 16 10 2024
Statut: epublish

Résumé

Ultrahigh-dose-rate therapy, also known as FLASH radiotherapy (RT), is an emerging technique that is garnering significant interest in cancer treatment due to its potential to revolutionize therapy. This method can achieve comparable tumor control to conventional-dose-rate RT while offering the enhanced protection of normal tissue through the FLASH-sparing effect. This innovative technique has demonstrated promising results in preclinical studies involving animals and cell lines. Particularly noteworthy is its potential application in treating head and neck (HN) cancers, especially in patients with challenging recurrent tumors and reirradiation cases, where the toxicity rates with conventional radiotherapy are high. Such applications aim to enhance tumor control while minimizing side effects and preserving patients' quality of life. In comparison to electron or photon FLASH modalities, proton therapy has demonstrated superior dosimetric and delivery characteristics and is a safe and effective FLASH treatment for human malignancies. Compared to the transmission proton FLASH, single-energy Bragg peak FLASH is a novel delivery method that allows highly conformal doses to targets and minimal radiation doses to crucial OARs. Proton Bragg peak FLASH for HN cancer has still not been well studied. This review highlights the significance of proton FLASH in enhancing cancer therapy by examining the advantages and challenges of using it for HN cancer reirradiation.

Identifiants

pubmed: 39409872
pii: cancers16193249
doi: 10.3390/cancers16193249
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Chingyun Cheng (C)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA.
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.

Liming Xu (L)

Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.

Hao Jing (H)

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Balaji Selvaraj (B)

New York Proton Center, New York, NY 10035, USA.

Haibo Lin (H)

New York Proton Center, New York, NY 10035, USA.

Michael Pennock (M)

Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461, USA.

Arpit M Chhabra (AM)

New York Proton Center, New York, NY 10035, USA.

Shaakir Hasan (S)

New York Proton Center, New York, NY 10035, USA.

Huifang Zhai (H)

New York Proton Center, New York, NY 10035, USA.

Yin Zhang (Y)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA.

Ke Nie (K)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA.

Richard L Bakst (RL)

Department of Radiation Oncology-Radiation Oncology Associates, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Rafi Kabarriti (R)

Department of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY 10461, USA.

J Isabelle Choi (JI)

New York Proton Center, New York, NY 10035, USA.
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Nancy Y Lee (NY)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Charles B Simone (CB)

New York Proton Center, New York, NY 10035, USA.
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Minglei Kang (M)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA.
New York Proton Center, New York, NY 10035, USA.

Hui Wu (H)

Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.

Classifications MeSH